Literature DB >> 2982971

The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma.

W L Alward, B J McMahon, D B Hall, W L Heyward, D P Francis, T R Bender.   

Abstract

One hundred fifty asymptomatic patients who were carriers of hepatitis B surface antigen (HBsAg) were studied serologically for up to 11.3 years (mean, 6.1 years). Only 9 (6.0%) lost HBsAg during the study period, for a mean annual clearance rate of 1.0%. We found no difference in the clearance of HBsAg by age, but a higher percentage of females lost HBsAg than did males (P less than .02). Hepatitis B e antigen (HBeAg) was found in 102 (68.5%) of the 149 carriers of HBsAg who were tested. Carriers of HBsAg who were seropositive for HBeAg were younger than those who were seronegative for HBeAg (P less than .01). The prevalence of HBeAg was not affected by the patients' sex. The clearance of HBeAg was gradual; 9.6% of the HBsAg carriers lost HBeAg each year. Females were more likely to clear HBeAg than were males (P less than .01), and those who cleared HBeAg were older than those who did not (P less than .01). Three (2.0%) of the HBsAg carriers developed primary hepatocellular carcinoma during the study period.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982971     DOI: 10.1093/infdis/151.4.604

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Current status of antiviral therapy for hepatitis B.

Authors:  Daryl T-Y Lau; Wissam Bleibel
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 3.  Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies.

Authors:  Ralph Carmel; Mona Sarrai
Journal:  Curr Hematol Rep       Date:  2006-03

4.  Evaluation of enzyme immunoassay (EIA) as a screening method for hepatitis B markers in an open population.

Authors:  J A McCready; D Morens; H A Fields; P J Coleman; M Kane; G Schatz
Journal:  Epidemiol Infect       Date:  1991-12       Impact factor: 2.451

Review 5.  Update on chronic viral hepatitis.

Authors:  K Walsh; G J Alexander
Journal:  Postgrad Med J       Date:  2001-08       Impact factor: 2.401

6.  Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas.

Authors:  W J Edmunds; G F Medley; D J Nokes; C J O'Callaghan; H C Whittle; A J Hall
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

7.  Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S.

Authors:  M'Kiaira K Miriti; Kaafee Billah; Cindy Weinbaum; Julie Subiadur; Richard Zimmerman; Paula Murray; Robert Gunn; Joanna Buffington
Journal:  Public Health Rep       Date:  2008 Jul-Aug       Impact factor: 2.792

8.  The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes.

Authors:  J R Williams; D J Nokes; G F Medley; R M Anderson
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

9.  HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection.

Authors:  Man-Fung Yuen; Danny Ka-Ho Wong; He-Jun Yuan; Siu-Man Sum; Ching-Lung Lai
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

10.  Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.

Authors:  L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-01       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.